
{
  "Company Overview": {
    "Name": "Maitreya Medicare Ltd",
    "Sector": "Healthcare",
    "Industry": "Healthcare",
    "Description": "Incorporated in 2019, Maitreya Medicare Ltd is an integrated multispeciality hospital with primary, secondary & tertiary care situated in Surat, Gujrat. Maitreya Medicare offers a comprehensive range of healthcare services across over 18 specialties and super specialties, including Cardiology, Urology, Laparoscopic Surgery, Oncology, Neurosurgery, Spine Surgery, Neurology, Nephrology including Dialysis, Gastroenterology, Gastrointestinal surgery, Cardiothoracic Surgery, Oncosurgery, Orthopedic Surgery including joint replacements and Arthroscopic surgeries, Gynecology & High-Risk Obstetrics, Hepatocellular Billary Surgery, Critical Care Medicine, etc.",
    "MarketPosition": null 
  },
  "Financial Metrics": {
    "MarketCap": "₹ 221 Cr.",
    "CurrentPrice": "₹ 327",
    "High/Low": "₹ 400 / ₹ 111",
    "PEratio": 70.7,
    "BookValue": "₹ 47.2",
    "DividendYield": "0.00%",
    "ROCE": "18.0%",
    "ROE": "18.6%",
    "FaceValue": "₹ 10.0",
    "DebtToEquityRatio": null
  },
  "PerformanceTrends": {
    "QuarterlyResults": {
      "Sep 2023": {
        "Sales": "24.79",
        "Expenses": "20.23",
        "OperatingProfit": "4.56",
        "OPM%": "18.39%",
        "OtherIncome": "0.05",
        "Interest": "0.39",
        "Depreciation": "0.64",
        "ProfitBeforeTax": "3.58",
        "Tax%": "28.49%",
        "NetProfit": "2.56",
        "EPS": "5.16"
      },
      "Sep 2024": {
        "Sales": "24.36",
        "Expenses": "21.18",
        "OperatingProfit": "3.18",
        "OPM%": "13.05%",
        "OtherIncome": "0.19",
        "Interest": "0.45",
        "Depreciation": "0.66",
        "ProfitBeforeTax": "2.26",
        "Tax%": "26.11%",
        "NetProfit": "1.67",
        "EPS": "2.46"
      }
    },
    "AnnualResults": {
      "Mar 2021": {
        "Sales": "55.93",
        "Expenses": "48.68",
        "OperatingProfit": "7.25",
        "OPM%": "12.96%",
        "OtherIncome": "0.43",
        "Interest": "0.82",
        "Depreciation": "1.09",
        "ProfitBeforeTax": "5.77",
        "Tax%": "26.52%",
        "NetProfit": "4.24",
        "EPS": "4240.00",
        "DividendPayout%": "0.00%"
      },
      "Mar 2022": {
        "Sales": "49.35",
        "Expenses": "45.98",
        "OperatingProfit": "3.37",
        "OPM%": "6.83%",
        "OtherIncome": "0.33",
        "Interest": "0.78",
        "Depreciation": "1.32",
        "ProfitBeforeTax": "1.60",
        "Tax%": "28.75%",
        "NetProfit": "1.14",
        "EPS": "1140.00",
        "DividendPayout%": "0.00%"
      },
      "Mar 2023": {
        "Sales": "39.28",
        "Expenses": "32.02",
        "OperatingProfit": "7.26",
        "OPM%": "18.48%",
        "OtherIncome": "0.53",
        "Interest": "0.57",
        "Depreciation": "1.29",
        "ProfitBeforeTax": "5.93",
        "Tax%": "28.16%",
        "NetProfit": "4.25",
        "EPS": "8.57",
        "DividendPayout%": "0.00%"
      },
      "Mar 2024": {
        "Sales": "46.13",
        "Expenses": "39.93",
        "OperatingProfit": "6.20",
        "OPM%": "13.44%",
        "OtherIncome": "0.30",
        "Interest": "0.84",
        "Depreciation": "1.27",
        "ProfitBeforeTax": "4.39",
        "Tax%": "27.79%",
        "NetProfit": "3.17",
        "EPS": "4.68",
        "DividendPayout%": "0.00%"
      }
    },
    "BalanceSheetHighlights": {
      "Mar 2021": {
        "EquityCapital": "0.01",
        "Reserves": "3.85",
        "Borrowings": "14.24",
        "OtherLiabilities": "7.17",
        "TotalLiabilities": "25.27",
        "FixedAssets": "13.84",
        "CWIP": "0.00",
        "Investments": "1.07",
        "OtherAssets": "10.36",
        "TotalAssets": "25.27"
      },
      "Mar 2022": {
        "EquityCapital": "0.01",
        "Reserves": "4.70",
        "Borrowings": "12.38",
        "OtherLiabilities": "7.40",
        "TotalLiabilities": "24.49",
        "FixedAssets": "13.40",
        "CWIP": "0.00",
        "Investments": "0.32",
        "OtherAssets": "10.77",
        "TotalAssets": "24.49"
      },
      "Mar 2023": {
        "EquityCapital": "4.96",
        "Reserves": "3.81",
        "Borrowings": "11.59",
        "OtherLiabilities": "8.55",
        "TotalLiabilities": "28.91",
        "FixedAssets": "11.60",
        "CWIP": "0.00",
        "Investments": "0.68",
        "OtherAssets": "16.63",
        "TotalAssets": "28.91"
      },
      "Mar 2024": {
        "EquityCapital": "6.78",
        "Reserves": "18.07",
        "Borrowings": "11.10",
        "OtherLiabilities": "7.91",
        "TotalLiabilities": "43.86",
        "FixedAssets": "14.32",
        "CWIP": "0.00",
        "Investments": "1.47",
        "OtherAssets": "28.07",
        "TotalAssets": "43.86"
      },
      "Sep 2024": {
        "EquityCapital": "12.22",
        "Reserves": "19.74",
        "Borrowings": "5.66",
        "OtherLiabilities": "9.36",
        "TotalLiabilities": "46.98",
        "FixedAssets": "15.05",
        "CWIP": "0.00",
        "Investments": "0.04",
        "OtherAssets": "31.89",
        "TotalAssets": "46.98"
      }
    },
    "CashFlowSummaries": {
      "Mar 2021": {
        "CashFromOperatingActivity": "4.45",
        "CashFromInvestingActivity": "-5.07",
        "CashFromFinancingActivity": "2.16",
        "NetCashFlow": "1.55"
      },
      "Mar 2022": {
        "CashFromOperatingActivity": "0.08",
        "CashFromInvestingActivity": "-0.02",
        "CashFromFinancingActivity": "-1.86",
        "NetCashFlow": "-1.80"
      },
      "Mar 2023": {
        "CashFromOperatingActivity": "2.59",
        "CashFromInvestingActivity": "0.36",
        "CashFromFinancingActivity": "-1.59",
        "NetCashFlow": "1.36"
      },
      "Mar 2024": {
        "CashFromOperatingActivity": "-2.15",
        "CashFromInvestingActivity": "-5.44",
        "CashFromFinancingActivity": "12.21",
        "NetCashFlow": "4.62"
      }
    }
  },
  "Ratios": {
    "GrowthRatios": {
      "CompoundedSalesGrowth_10Years": null,
      "CompoundedSalesGrowth_5Years": null,
      "CompoundedSalesGrowth_3Years": "-6%",
      "CompoundedSalesGrowth_TTM": "17%"
    },
    "ProfitabilityRatios": {
      "CompoundedProfitGrowth_10Years": null,
      "CompoundedProfitGrowth_5Years": null,
      "CompoundedProfitGrowth_3Years": "-9%",
      "CompoundedProfitGrowth_TTM": "-27%"
    },
    "LiquidityRatios": {
      "DebtorDays_Mar2021": "31.91",
      "DebtorDays_Mar2022": "43.42",
      "DebtorDays_Mar2023": "90.41",
      "DebtorDays_Mar2024": "108.40",
      "InventoryDays_Mar2021": "68.78",
      "InventoryDays_Mar2022": "40.82",
      "InventoryDays_Mar2023": "69.86",
      "InventoryDays_Mar2024": "40.26",
      "DaysPayable_Mar2021": "258.06",
      "DaysPayable_Mar2022": "221.84",
      "DaysPayable_Mar2023": "319.59",
      "DaysPayable_Mar2024": "207.25",
      "CashConversionCycle_Mar2021": "-157.37",
      "CashConversionCycle_Mar2022": "-137.61",
      "CashConversionCycle_Mar2023": "-159.32",
      "CashConversionCycle_Mar2024": "-58.59",
      "WorkingCapitalDays_Mar2021": "3.65",
      "WorkingCapitalDays_Mar2022": "12.28",
      "WorkingCapitalDays_Mar2023": "43.58",
      "WorkingCapitalDays_Mar2024": "84.11"
    },
    "ValuationRatios": {
      "PriceToBook": null,
      "MarketCapToSales": null,
      "EVtoEBITDA": null
    },
    "OtherRatios": {
      "ROCE_Mar2021": "12.33%",
      "ROCE_Mar2022": "32.85%",
      "ROCE_Mar2023": "18.00%",
      "ROE_10Years": null,
      "ROE_5Years": null,
      "ROE_3Years": "30%",
      "ROE_LastYear": "19%"
    }
  },
  "PeerComparison": {
    "Peers": [
      {"Name": "Max Healthcare", "CMP": "1165.20", "PE": "106.97", "MarCap": "113272.83", "DivYld": "0.13", "NPQtr": "281.81", "QtrProfitVar": "1.85", "SalesQtr": "1707.46", "QtrSalesVar": "25.26", "ROCE": "16.00"},
      {"Name": "Apollo Hospitals", "CMP": "7251.70", "PE": "88.13", "MarCap": "104268.32", "DivYld": "0.22", "NPQtr": "395.70", "QtrProfitVar": "63.46", "SalesQtr": "5589.30", "QtrSalesVar": "15.32", "ROCE": "15.11"},
      {"Name": "Fortis Health.", "CMP": "677.85", "PE": "74.39", "MarCap": "51174.84", "DivYld": "0.15", "NPQtr": "193.08", "QtrProfitVar": "26.85", "SalesQtr": "1988.39", "QtrSalesVar": "12.34", "ROCE": "10.34"},
      {"Name": "Global Health", "CMP": "1098.60", "PE": "60.47", "MarCap": "29507.01", "DivYld": "0.00", "NPQtr": "130.81", "QtrProfitVar": "4.51", "SalesQtr": "956.56", "QtrSalesVar": "13.34", "ROCE": "19.32"},
      {"Name": "Narayana Hrudaya", "CMP": "1288.10", "PE": "33.80", "MarCap": "26323.72", "DivYld": "0.31", "NPQtr": "198.80", "QtrProfitVar": "-12.34", "SalesQtr": "1400.01", "QtrSalesVar": "7.26", "ROCE": "26.54"},
      {"Name": "Poly Medicure", "CMP": "2595.75", "PE": "89.20", "MarCap": "26301.62", "DivYld": "0.12", "NPQtr": "87.45", "QtrProfitVar": "40.62", "SalesQtr": "420.02", "QtrSalesVar": "24.53", "ROCE": "23.62"},
      {"Name": "Dr Lal Pathlabs", "CMP": "2946.25", "PE": "61.35", "MarCap": "24625.42", "DivYld": "0.81", "NPQtr": "130.80", "QtrProfitVar": "18.21", "SalesQtr": "660.20", "QtrSalesVar": "9.80", "ROCE": "25.17"},
      {"Name": "Maitreya", "CMP": "326.75", "PE": "70.74", "MarCap": "221.41", "DivYld": "0.00", "NPQtr": "1.67", "QtrProfitVar": "-27.39", "SalesQtr": "24.36", "QtrSalesVar": "-1.73", "ROCE": "18.00"}
    ],
    "Median": {
      "CMP": "572.25",
      "PE": "60.91",
      "MarCap": "4461.75",
      "DivYld": "0.13",
      "NPQtr": "21.97",
      "QtrProfitVar": "25.87",
      "SalesQtr": "182.95",
      "QtrSalesVar": "14.06",
      "ROCE": "18.72"
    }
  },
  "OtherInsights": {
    "Pros": [
      "Company has reduced debt.",
      "Company has a good return on equity (ROE) track record: 3 Years ROE 30.5%"
    ],
    "Cons": [
      "Though the company is reporting repeated profits, it is not paying out dividend",
      "Debtor days have increased from 80.7 to 108 days.",
      "Working capital days have increased from 46.7 days to 84.1 days"
    ],
    "Disclaimer": "* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.",
    "ShareholdingPattern": {
      "Mar 2024": {
        "Promoters": "73.11%",
        "FIIs": "2.53%",
        "DIIs": "1.35%",
        "Public": "23.02%",
        "NoOfShareholders": "474"
      },
      "Sep 2024": {
        "Promoters": "73.11%",
        "FIIs": "0.41%",
        "DIIs": "0.00%",
        "Public": "26.48%",
        "NoOfShareholders": "907"
      },
      "Disclaimer": "* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards. Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes. Click on the line-items to see the names of individual entities."
    }
  },
  "Documents": {
    "Announcements": [
      {"Date": "9 December 2024", "Title": "Outcome of Board Meeting"},
      {"Date": "18 November 2024", "Title": "Reply to Clarification- Financial results"},
      {"Date": "12 November 2024", "Title": "Clarification - Financial Results"},
      {"Date": "11 November 2024", "Title": "Analysts/Institutional Investor Meet/Con. Call Updates"},
      {"Date": "8 November 2024", "Title": "Analysts/Institutional Investor Meet/Con. Call Updates"}
    ],
    "AnnualReports": [
      {"Year": "2024", "Source": "nse"}
    ],
    "Concalls": [
      {"Month": "Nov 2024", "Materials": ["Transcript", "Notes", "PPT"]},
      {"Month": "May 2024", "Materials": ["Transcript", "Notes", "PPT"]},
      {"Month": "Feb 2024", "Materials": ["Transcript", "Notes", "PPT"]}
    ]
  }
}
